mannitol has been researched along with Melanoma in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (22.73) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (54.55) | 29.6817 |
| 2010's | 3 (13.64) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Balan, S; Bhardwaj, N; Blazquez, AB; Gimenez, G; Gnjatic, S; Holman, RM; Lattanzi, M; Mandeli, J; Marron, TU; McClain, CB; Meseck, M; Ott, PA; Pavlick, A; Sabado, RL; Salazar, AM | 1 |
| Koeppel, AF; Kumar, P; Lynch, KT; Mauldin, IS; Melssen, MM; Meneveau, MO; Pollack, KE; Slingluff, CL; Sol-Church, K; Turner, S; Young, SJ | 1 |
| Clancy-Thompson, E; King, LK; Mullins, DW; Mullins, IM; Nunnley, LD; Slingluff, CL | 1 |
| Adams, S; Bhardwaj, N; Chiriboga, L; Cruz, CM; Darvishian, F; Escalon, J; Escano, C; Gnjatic, S; Goldberg, J; Hasan, F; Holman, RM; Jungbluth, A; Mandeli, J; Muren, C; Ott, PA; Pan, L; Pavlick, A; Rolnitzsky, L; Sabado, RL; Sharpe, D; Spadaccia, M; Vasilakos, JP; Vengco, I; Venhaus, R; Yepes, E | 1 |
| Andrade Filho, PA; Donnenberg, A; Fourcade, J; Janjic, B; Kirkwood, JM; Krieg, A; Kudela, P; Land, SR; Sander, C; Shen, H; Zarour, HM | 1 |
| Altorki, NK; Bender, A; Ferrara, CA; Gnjatic, S; Hoffmann, E; Jäger, E; Karbach, J; Neumann, A; Old, LJ; Weidmann, E; Yuan, J | 1 |
| HUMBLE, JG; NEWTON, KA; PEGG, DE; SKINNER, ME; WESTBURY, G | 1 |
| Barnd, DL; Chianese-Bullock, KA; Deacon, DH; Eastham, S; Engelhard, VH; Galavotti, H; Gibson, J; Grosh, WW; Hibbitts, S; Merrill, P; Neese, PY; Patterson, JW; Petroni, GR; Ross, M; Slingluff, CL; Teates, D; Wiernasz, CJ; Woodson, EM; Yamshchikov, GV | 1 |
| Collins, S; Coventry, B; Farrelly, M; Hersey, P; Hirst, D; Johnson, H; Menzies, SW; Nguyen, T | 1 |
| Dranoff, G | 1 |
| Davis, T; Groshen, S; Keler, T; Lee, P; Liu, D; Nichol, G; Sanderson, K; Scotland, R; Sian, S; Snively, J; Weber, J; Yellin, M | 1 |
| Bissonette, EA; Chianese-Bullock, KA; Fink, R; Garbee, C; Grosh, WW; Hibbitts, S; Merrill, P; Murphy, C; Neese, PY; Patterson, JW; Petroni, GR; Pressley, J; Slingluff, CL; Wiernasz, CJ; Woodson, EM; Yamshchikov, G | 1 |
| Allred, JB; Celis, E; Creagan, ET; Ingle, JN; Kaur, JS; Loprinzi, CL; Markovic, SN; Nevala, WK; Pitot, HC; Pittelkow, MR; Rao, RD; Suman, VJ | 1 |
| Celis, E | 1 |
| Alonso, D; Anasagasti, L; Arango, Mdel C; Carr, A; Fernández, LE; Gómez, E; González, J; González, JL; Gracia, E; Joan, A; Melgares, Mde L; Noris, E; Osorio, M; Pérez, R; Rengifo, E; Rodríguez, E; Saurez, G; Torres, I; Torriella, A | 1 |
| Atkins, MB; Carrillo, C; Clark, JI; Crosby, NA; Dutcher, J; Ernstoff, MS; Flaherty, L; Gollob, J; Kirkwood, JM; LaFleur, B; Margolin, KA; Mier, J; O'Boyle, K; Panka, DJ; Sosman, JA; Urba, WJ | 1 |
| Al-Sarraf, M; Balducci, L; Fletcher, W; Hewlett, JS; McCracken, J; Oishi, N; Padilla, F; Pugh, R | 1 |
| Barth, RF; Bartus, RT; Coderre, JA; Ferketich, AK; Moeschberger, ML; Nawrocky, MM; Rofstad, EK; Rotaru, JH; Yang, W | 1 |
| Batard, P; Cerottini, JC; Guillaume, P; Liénard, D; Pittet, MJ; Rimoldi, D; Romero, P; Speiser, DE | 1 |
| Swanson, TL | 1 |
| Keogh, JA; Lamb, JD | 1 |
| Barnett, PA; Brown, P; Dahlborg, SA; Eckerman, KF; Hellström, I; Hellström, KE; Larson, SM; Miley, A; Neuwelt, EA; Specht, HD | 1 |
11 trial(s) available for mannitol and Melanoma
| Article | Year |
|---|---|
Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
Topics: Adjuvants, Immunologic; Aged; Antigens, Neoplasm; Cancer Vaccines; Carboxymethylcellulose Sodium; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Priming; Female; Humans; Immunity, Cellular; Immunity, Humoral; Interferon Inducers; Male; Mannitol; Melanoma; Membrane Proteins; Middle Aged; Oleic Acids; Patient Safety; Poly I-C; Polylysine; Skin Neoplasms; Treatment Outcome | 2020 |
Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells.
Topics: Amino Acid Sequence; Antigens, Neoplasm; Cancer Vaccines; CD8-Positive T-Lymphocytes; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Mannitol; Melanoma; Molecular Sequence Data; Neoplasm Proteins; Oleic Acids; Peptides; Receptors, CXCR3 | 2013 |
Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antibodies, Neoplasm; Antibody Formation; Antigens, Neoplasm; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Humans; Imidazoles; Immunity, Cellular; Male; Mannitol; Melanoma; Membrane Proteins; Middle Aged; Oleic Acids; Peptide Fragments; Vaccination | 2015 |
Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.
Topics: Aged; Aged, 80 and over; Cancer Vaccines; CD8-Positive T-Lymphocytes; Female; Humans; Immunization; Male; Mannitol; Melanoma; Middle Aged; Neoplasm Proteins; Oleic Acids; Oligodeoxyribonucleotides; Peptide Fragments; Pilot Projects; Skin Neoplasms; T-Lymphocytes, Cytotoxic | 2008 |
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Topics: Adult; Aged; Cancer Vaccines; Dendritic Cells; Drug Administration Schedule; Female; gp100 Melanoma Antigen; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Lymph Nodes; Male; Mannitol; Melanoma; Membrane Glycoproteins; Middle Aged; Monophenol Monooxygenase; Neoplasm Proteins; Oleic Acids; Peptide Fragments; Radiography; Skin Neoplasms; Survival Analysis; T-Lymphocytes; Thoracic Neoplasms; Treatment Outcome | 2003 |
Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Cytokines; Enzyme-Linked Immunosorbent Assay; Epitopes; Epitopes, T-Lymphocyte; Female; gp100 Melanoma Antigen; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypersensitivity, Delayed; Immunity, Cellular; Immunotherapy; Inflammation; Interferon-gamma; Lymphocytes; Male; Mannitol; MART-1 Antigen; Melanoma; Membrane Glycoproteins; Middle Aged; Monophenol Monooxygenase; Neoplasm Proteins; Oleic Acids; Peptides; Skin Neoplasms; Time Factors; Treatment Outcome | 2005 |
Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Cancer Vaccines; Female; gp100 Melanoma Antigen; Granulocyte-Macrophage Colony-Stimulating Factor; HLA-A2 Antigen; Humans; Hypersensitivity, Delayed; Immunophenotyping; Male; Mannitol; MART-1 Antigen; Melanoma; Membrane Glycoproteins; Middle Aged; Monophenol Monooxygenase; Neoplasm Proteins; Oleic Acids; Recombinant Proteins; Skin Neoplasms; Survival Analysis; Vaccines, Subunit | 2006 |
Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
Topics: Adult; Aged; Amino Acid Sequence; Cancer Vaccines; Dendritic Cells; Epitopes; Female; Freund's Adjuvant; Granulocyte-Macrophage Colony-Stimulating Factor; HLA Antigens; Humans; Lymphocyte Activation; Male; Mannitol; Melanoma; Middle Aged; Neoplasm Staging; Oleic Acids; Oligopeptides; Skin Neoplasms; Survival Analysis; Survival Rate; T-Lymphocytes, Cytotoxic; Treatment Outcome | 2007 |
Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study.
Topics: Adult; Aged; Bacterial Outer Membrane Proteins; Cancer Vaccines; Eye Neoplasms; Female; G(M3) Ganglioside; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Liposomes; Male; Mannitol; Melanoma; Middle Aged; Neisseria meningitidis; Oleic Acids; Skin Diseases; Survival Analysis; Treatment Outcome; Vaccination; Vitiligo | 2008 |
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Freund's Adjuvant; gp100 Melanoma Antigen; HLA-A2 Antigen; Humans; Interleukin-2; Male; Mannitol; Melanoma; Membrane Glycoproteins; Middle Aged; Oleic Acids | 2008 |
Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study.
Topics: Cisplatin; Humans; Kidney Diseases; Mannitol; Melanoma; Water-Electrolyte Balance | 1982 |
11 other study(ies) available for mannitol and Melanoma
| Article | Year |
|---|---|
Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Arginase; Biopsy; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD40 Ligand; Clinical Trials, Phase I as Topic; Female; Freund's Adjuvant; Humans; Immunization, Secondary; Immunogenicity, Vaccine; Injections, Intralesional; Lipids; Male; Mannitol; Melanoma; Middle Aged; Oleic Acids; Randomized Controlled Trials as Topic; Signal Transduction; Skin; Skin Neoplasms; Th1 Cells; Toll-Like Receptors; Tumor Microenvironment; Vaccination; Vaccines, Subunit; Young Adult | 2020 |
Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
Topics: Antigens, Neoplasm; Breast Neoplasms; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Flow Cytometry; Humans; Immunotherapy; Mannitol; Melanoma; Membrane Proteins; Neoplasm Staging; Neoplasms; Oleic Acids; Oligodeoxyribonucleotides; Ovarian Neoplasms; Sarcoma; Vaccination | 2010 |
Disseminated malignant melanoma: response to treatment by massive dosage of a cytotoxic agent combined with autogenous marrow replacement.
Topics: Antineoplastic Agents; Bone Marrow; Cytotoxins; Mannitol; Mechlorethamine; Melanoma; Nitrogen Mustard Compounds; Vegetables | 1959 |
CTLA-4 blockade: unveiling immune regulation.
Topics: Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation; Autoimmunity; Cancer Vaccines; CTLA-4 Antigen; Humans; Mannitol; Melanoma; Oleic Acids | 2005 |
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.
Topics: Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation; Antigens, Neoplasm; Autoimmunity; Cancer Vaccines; CTLA-4 Antigen; Female; Flow Cytometry; gp100 Melanoma Antigen; Humans; Male; Mannitol; MART-1 Antigen; Melanoma; Membrane Glycoproteins; Middle Aged; Monophenol Monooxygenase; Neoplasm Proteins; Neoplasm Staging; Oleic Acids; Peptide Fragments; Receptors, CCR; Receptors, Chemokine; Vaccination | 2005 |
MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
Topics: Adjuvants, Immunologic; Amino Acid Sequence; Antigens, Neoplasm; Antineoplastic Agents; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Transformed; Cell Line, Tumor; Cytotoxicity Tests, Immunologic; gp100 Melanoma Antigen; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymph Nodes; Mannitol; Melanoma; Melanoma-Specific Antigens; Membrane Glycoproteins; Molecular Sequence Data; Neoplasm Proteins; Oleic Acids; Peptide Fragments; Protein Binding; Vaccines, Combined; Vaccines, Subunit | 2005 |
Neutron capture therapy of intracerebral melanoma: enhanced survival and cure after blood-brain barrier opening to improve delivery of boronophenylalanine.
Topics: Animals; Blood-Brain Barrier; Boron Compounds; Boron Neutron Capture Therapy; Bradykinin; Brain Neoplasms; Humans; Mannitol; Melanoma; Osmosis; Phenylalanine; Radiation-Sensitizing Agents; Rats; Rats, Nude | 2002 |
In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells.
Topics: Adjuvants, Immunologic; Antigens, Neoplasm; Antigens, Viral; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Differentiation; Cytomegalovirus; HLA-A2 Antigen; HLA-DR Antigens; Humans; Immunologic Memory; Immunotherapy; Influenza A virus; Lymphocyte Activation; Mannitol; MART-1 Antigen; Melanoma; Neoplasm Proteins; Oleic Acids; Peptide Fragments; Vaccines, Subunit; Viral Matrix Proteins | 2002 |
The growth response of cells in medium made hyperosmolal with electrolytes or mannitol.
Topics: Carcinoma, Transitional Cell; Cell Division; Cell Line; Cells, Cultured; Culture Media; Humans; Lymphocytes; Mannitol; Melanoma; Osmolar Concentration; Potassium Chloride; Sodium Chloride; Urinary Bladder Neoplasms | 1979 |
Anaphylactoid reaction to mannitol.
Topics: Adolescent; Anaphylaxis; Drug Hypersensitivity; Edema; Eye Neoplasms; Humans; Male; Mannitol; Melanoma; Respiratory Insufficiency | 1979 |
Increased delivery of tumor-specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to the central nervous system.
Topics: Antibodies, Monoclonal; Antibodies, Neoplasm; Blood-Brain Barrier; Brain Neoplasms; Humans; Mannitol; Melanoma | 1987 |